Anixa Biosciences, Inc.
Company Snapshot: Anixa Biosciences, Inc.
Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization. Additional information is available at www.anixa.com.
- Dec 19 2022 Anixa Biosciences to Present at Biotech Showcase 2023
- Dec 8 2022 Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine
- Nov 8 2022 Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium
- Oct 31 2022 Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss Anixa Biosciences' Ovarian Cancer CAR-T Therapy